Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.

MLA

Samol, Jens, et al. “Safety and Tolerability of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitor, Olaparib (AZD2281) in Combination with Topotecan for the Treatment of Patients with Advanced Solid Tumors: A Phase I Study.” Investigational New Drugs, vol. 30, no. 4, Aug. 2012, pp. 1493–500. EBSCOhost, https://doi.org/10.1007/s10637-011-9682-9.

APA

Samol, J., Ranson, M., Scott, E., Macpherson, E., Carmichael, J., Thomas, A., & Cassidy, J. (2012). Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Investigational New Drugs, 30(4), 1493–1500. https://doi.org/10.1007/s10637-011-9682-9

Chicago

Samol, Jens, Malcolm Ranson, Edwina Scott, Euan Macpherson, James Carmichael, Anne Thomas, and James Cassidy. 2012. “Safety and Tolerability of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitor, Olaparib (AZD2281) in Combination with Topotecan for the Treatment of Patients with Advanced Solid Tumors: A Phase I Study.” Investigational New Drugs 30 (4): 1493–1500. doi:10.1007/s10637-011-9682-9.